Incorporating new data on colorectal cancer into nursing practice

Clinical Journal of Oncology Nursing

Volumn 14, Issue 1, 2010, Pages 92-100

  Viale, Pamela Hallquist ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CALCIUM; EPIDERMAL GROWTH FACTOR RECEPTOR; MAGNESIUM; OXALIPLATIN; PLATINUM COMPLEX;

ARTICLE; COLORECTAL TUMOR; DRUG ANTAGONISM; HUMAN; MUTATION; NURSING; ONCOGENE RAS; ONCOLOGY NURSING; TOXICITY AND INTOXICATION;

ANTINEOPLASTIC AGENTS; CALCIUM; COLORECTAL NEOPLASMS; GENES, RAS; HUMANS; MAGNESIUM; MUTATION; NEUROTOXICITY SYNDROMES; ONCOLOGIC NURSING; ORGANOPLATINUM COMPOUNDS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 77956650610     PISSN: 10921095     EISSN: 1538067X     Source Type: Journal    
DOI: 10.1188/10.CJON.92-100     Document Type: Article

References (52)

1. Abraham, J. (2008). KRAS status as a predictor of response to EGFR inhibitors in mCRC. Community Oncology, 5, 433-435. Retrieved from http://www.communityoncology.net/journal/articles/0508433.pdf
2. Agero, A.L., Dusza, S.W., Benvenuto-Andrade, C., Busam, K.J., Myskowski, P., & Halpern, A.C. (2006). Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. Journal of the American Academy of Dermatology, 55, 657-670. doi: 10.1016/j.jaad.2005.10.010
3. Allegra, C.J., Jessup, J.M., Somerfield, M.R., Hamilton, S.R., Hammond, E.H., Hayes, D.F., Schilsky, R.L. (2009). American Society of Clinical Oncology provisional clinical opinion: Testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody. Retrieved from http://jco.ascopubs.org/cgi/content/abstract/JCO.2009.21.9170v1
4. Amado, R.G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D.J., Chang, D.D. (2008). Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. Journal of Clinical Oncology, 26, 1626-1634. doi: 10.1200/JCO.2007.14.7116
5. ® (panitumumab) [Package insert]. Retrieved from http://www.vectibix.com/pdfs/misc/vectibix_pi.pdf
6. Baselga, J., & Rosen, N. (2008). Determinants of RASistance to anti-epidermal growth factor receptor agents. Journal of Clinical Oncology, 26, 1582-1584. doi: 10.1200/JCO.2007.15.3700
7. ® (cetuximab) [Package insert]. Princeton, NJ: Author. Retrieved from http://packageinserts.bms.com/pi/pi_erbitux.pdf
8. Burtness, B., Anadkat, M., Basti, S., Hughes, M., Lacouture, M.E., McClure, J.S., Spencer, S. (2009). NCCN task force report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer. Journal of the National Comprehensive Cancer Network, 7(Suppl. 1), S5-S21. Retrieved from http://www.nccn.org/JNCCN/PDF/2009_Derm_Tox_TF.pdf
9. Choo, S., Tan, S., Lo, H., Ng, K., Foo, K., & Ong, S. (2009). Use of intravenous calcium and magnesium infusion in preventing oxaliplatin-induced sensory neuropathy [Abstract 416]. Retrieved from http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=63&abstractID=10345
10. Chung, C.H., Mirakhur, B., Chan, E., Le, Q.T., Berlin, J., Morse, M., Platts-Mills, T.A. (2008). Cetuximab-induced anaphylaxis and IgE specific for galactose-a-1,3-galactose. New England Journal of Medicine, 358, 1109-1117.
11. Chung, C.H., & O'Neil, B.H. (2009). Infusion reactions to monoclonal antibodies for solid tumors: Immunologic mechanisms and risk factors. Oncology, 23(Suppl.), 14-17. Retrieved from http://content.nejm.org/cgi/content/full/358/11/1109
12. Cmelak, A.J., Lordick, F., Borner, M., Goldberg, R.M., & Saif, M.W. (2009). Management of infusion reactions in clinical trials and beyond: The US and EU perspectives. Oncology, 23(2, Suppl. 1), 18-25. Retrieved from http://www.cancernetwork.com/head-and-neck-cancer/article/10165/1382797?verify=0
13. Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Van Cutsem, E. (2004). Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. New England Journal of Medicine, 351, 337-345. Retrieved from http://content.nejm.org/cgi/content/full/351/4/337
14. De Roock, W., Piessevaux, H., De Schutter, J., Janssens, M., De Hertogh, G., Personeni, N., Tejpar, S. (2008). KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Annals of Oncology, 19, 508-515. doi: 10.1093/annonc/mdm496
15. Eaby, B., Culkin, A., & Lacouture, M.E. (2008). An interdisciplinary consensus on managing skin reactions associated with human epidermal growth factor receptor inhibitors. Clinical Journal of Oncology Nursing, 12, 283-290. doi: 10.1188/08.CJON.283-290
16. Galimont-Collen, A.F.S., Vos, L.E., Lavrijsen, A.P.M., Ouwerkerk, J., & Gelderblom, H. (2007). Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors. European Journal of Cancer, 43, 845-851. doi: 10.1016/j.ejca.2006.11.016
17. Gamelin, L., Boisdron-Celle, M., Delva, R., Guerin-Meyer, V., Ifrah, N., Morel, A., & Gamelin, E. (2004). Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: A retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clinical Cancer Research, 10(12, Pt. 1), 4055-4061.
18. Gamelin, L., Boisdron-Celle, M., Morel, A., Poirier, A.L., Berger, V., Gamelin, E., de Gramont, A. (2008). Oxaliplatin-related neurotoxicity: Interest of calcium-magnesium infusion and no impact on its efficacy. Journal of Clinical Oncology, 26, 1188-1189. doi: 10.1200/JCO.2007.15.3767
19. Gamelin, L., Boisdron-Celle, M., Poirier, A.L., Berger, V., Morel, A., & Gamelin, E. (2007). Prevention of oxaliplatin-induced neurotoxicity with Ca2+/Mg2+ infusions: Preliminary results of the NEUROXA randomized trial in patients with colorectal cancer (CRC) receiving the FOLFOX4 regimen [Abstract 602]. Retrieved from http://www.isgio.org/isgio2007/pdf/accancer/gamelin.pdf
20. George, T.J., Jr. (2008). KRAS mutational analysis: Ready for prime time? Community Oncology, 5, 435-436. Retrieved from http://www.communityoncology.net/journal/articles/0508433.pdf
21. Grothey, A., & Turja, J.H. (2008). Optimizing therapy by minimizing toxicities in the treatment of colorectal cancer: American Society of Clinical Oncology (ASCO) 44th Annual Meeting. Retrieved from http://www.medscape.com/viewarticle/577625
22. Hochster, H.S., Grothey, A., & Childs, B.H. (2007). Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity. Journal of Clinical Oncology, 25, 4028-4029. doi: 10.1200/JCO.2007.13.5251
23. Hochster, H.S., Grothey, A., Shpilsky, A., & Childs, B.H. (2008). Effect of intravenous (IV) calcium and magnesium (Ca/Mg) versus placebo on response to FOLFOX+bevacizumab (BEV) in the CONcePT trial [Abstract 280]. Retrieved from http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=53&abstractID=10402
24. Hu, J.C., Sadeghi, P., Pinter-Brown, L.C., Yashar, S., & Chiu, M.W. (2007). Cutaneous side effects of epidermal growth factor receptor inhibitors: Clinical presentation, pathogenesis, and management. Journal of the American Academy of Dermatology, 56, 317-326. doi: 10.1016/j.jaad.2006.09.005
25. Jatoi, A., Rowland, K., Sloan, J.A., Gross, H.M., Fishkin, P.A., Kahanic, S.P., Loprinzi, C.L. (2008). Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer, 113, 847-853. doi: 10.1002/cncr.23621
26. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M.J. (2009). Cancer statistics, 2009. CA: A Cancer Journal for Clinicians, 59, 225-249. doi: 10.3322/caac.20006
27. Karapetis, C.S., Khambata-Ford, S., Jonker, D.J., O'Callaghan, C.J., Tu, D., Tebbutt, N.C., Zalcberg, J.R. (2008). K-ras mutations and benefit from cetuximab in advanced colorectal cancer. New England Journal of Medicine, 359, 1757-1765. Retrieved from http://content.nejm.org/cgi/content/full/359/17/1757
28. Katzer, K., Tietze, J., Klein, E., Heinemann, V., Ruzicka, T., & Wollenberg, A. (2009). Topical therapy with nadifloxacin cream and prednicarbate cream improves acneiform eruptions caused by the EGFR-inhibitor cetuximab-A report of 29 patients. European Journal of Dermatology, 20, 1-3.
29. Khambata-Ford, S., Garrett, C.R., Meropol, N.J., Basik, M., Harbison, C.T., Wu, S., Mauro, D.J. (2007). Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. Journal of Clinical Oncology, 25, 3230-3237.
30. Lacouture, M.E., Mitchell, E.P., Shearer, H., Iannotti, N., Piperdi, B., Pillai, M.V., Yassine, M. (2009). Impact of pre-emptive skin toxicity (ST) treatment (tx) on panitumumab (pmab)-related skin toxicities and quality of life (QOL) in patients (pts) with metastatic colorectal cancer (mCRC): Results from STEPP [Abstract 291]. Retrieved from http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=63&abstractID=10396
31. Lenz, H.J., Van Cutsem, E., Khambata-Ford, S., Mayer, R.J., Gold, P., Stella, P., Rowinsky, E.K. (2006). Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluororpyrimidines. Journal of Clinical Oncology, 24, 4914-4921. doi: 10.1200/JCO.2006.06.7595
32. Lynch, T.J., Jr., Kim, E.S., Eaby, B., Garey, J., West, D.P., & LaCouture, M.E. (2007). Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: An evolving paradigm in clinical management. Oncologist, 12, 610-621. doi: 10.1634/theoncologist.12-5-610
33. Makhoul, I., Siegel, E., Hutchins, L., Maddox, A., Govindarajan, R., & Safar, M. (2008). Cetuximab-related first infusion reaction (FIR) in colorectal cancer (CRC) and other cancer (CA) patients (Pts.) [Abstract 381]. Retrieved from http://www.asco.org/ASCO/Abstracts+&+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=53&abstractID=10030
34. National Cancer Institute. (2009). Common Terminology Criteria for Adverse Events [v.4.02]. Retrieved from http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.02_2009-09-15_QuickReference_8.5x11.pdf
35. National Comprehensive Cancer Network. (2009). NCCN Clinical Practice Guidelines in Oncology™: Colon cancer [v.1.2010]. Retrieved from http://www.nccn.org/professionals/physician_gls/PDF/colon.pdf
36. Nikcevich, D.A., Grothey, A., Sloan, J.A., Kugler, J.W., Silberstein, P.T., Dentchev, T., Loprinzi, C.L. (2008). Effect of intravenous calcium and magnesium (IV CaMg) on oxaliplatin-induced sensory neurotoxicity (sNT) in adjuvant colon cancer: Results of the phase III placebo-controlled, double-blind NCCTG trial N04C7 [Abstract 4009]. Retrieved from http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=32445
37. Oishi, K. (2008). Clinical approaches to minimize rash associated with EGFR inhibitors. Oncology Nursing Forum, 35, 103-111. doi: 10.1188/08.ONF.103-111
38. O'Neil, B.H., Allen, R., Spigel, D.R., Stinchcombe, T.E., Moore, D.T., Berlin, J.D., & Goldberg, R.M. (2007). High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. Journal of Clinical Oncology, 25, 3644-3648. doi: 10.1200/JCO.2007.11.7812
39. Owera, R., Gill, A., Haddadin, S., Khozouz, R., & Perry, M.C. (2008). High incidence of hypersensitivity reactions to cetuximab infusions in mid-Missouri: Association with prior history of atopy [Abstract 20747]. Retrieved from http://meeting.ascopubs.org/cgi/content/abstract/26/15_suppl/20747
40. Park, S.B., Goldstein, D., Lin, C.S.-Y., Krishnan, A.V., Friedlander, M.L. & Kiernan, M.C. (2009). Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. Journal of Clinical Oncology, 27, 1243-1249. Retrieved from http://jco.ascopubs.org/cgi/reprint/JCO.2008.19.3425v2
41. Polyzos, A., Tsavaris, N., Gogas, H., Souglakos, J., Vambakas, L., Vardakas, N., Kouraklis, G. (2009). Clinical features of hypersensitivity reactions to oxaliplatin: A 10-year experience. Oncology (Karger), 76, 36-41. doi: 10.1159/000178163
42. Price, T., Pittman, K., Patterson, W., Colbeck, M., Rieger, N., Hewett, P., Roder, D. (2008). Management and survival trends in advanced colorectal cancer. Clinical Oncology(Royal College of Radiologists (Great Britain), 20, 626-630. doi: 10.1016/j.clon.2008.04.014
43. Saltz, L., Kies, M., Abbruzzese, J.L., Azarnia, N., & Needle, M. (2003). The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies [Abstract 817]. Retrieved from http://www.asco.org/ASCO/Abstracts+&+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=23&abstractID=102245
44. Sapadin, A.N., & Fleischmajer, R. (2006). Tetracyclines: Nonantibiotic properties and their clinical implications. Journal of the American Academy of Dermatology, 54, 258-265. doi: 10.1016/j.jaad.2005.10.004
45. Scope, A., Agero, A.L., Dusza, S.W., Myskowski, P.L., Lieb, J.A., Saltz, L., Halpern, A.C. (2007). Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. Journal of Clinical Oncology, 25, 5390-5396. doi: 10.1200/JCO.2007.12.6987
46. Scope, A., Lieb, J.A., Dusza, S.W., Phelan, D.L., Myskowski, P.L., Saltz, L., & Halpern, A.C. (2009). A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption. Journal of the American Academy of Dermatology, 61, 614-620. doi: 10.1016/j.jaad.2009.03.046
47. Sipples, R. (2006). Common side effects of anti-EGFR therapy: Acneform rash. Seminars in Oncology Nursing, 22(1, Suppl. 1), 28-34. doi: 10.1016/j.soncn.2006.01.013
48. Spano, J.P., Milano, G., Vignot, S., & Khayat, D. (2008). Potential predictive markers of response to EGFR-targeted therapies in colorectal cancer. Critical Reviews in Oncology/Hematology, 66, 21-30. doi: 10.1016/j.critrevonc.2007.11.005
49. Viale, P.H. (2009). Management of hypersensitivity reactions: A nursing perspective. Oncology, 23(2, Suppl. 1), 26-30. Retrieved from http://www.cancernetwork.com/supplements/2009/infusion-reactions/display/article/10165/1382802?verify=0
50. Vincenzi, B., Santini, D., Rabitti, C., Coppola, R., Beomonte Zobel, B., Trodella, L., & Tonini, G. (2006). Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: A single centre phase II trial. British Journal of Cancer, 94, 792-797. doi: 10.1038/sj.bjc.6603018
51. Webster, G., & Del Rosso, J.Q. (2007). Anti-inflammatory activity of tetracyclines. Dermatologic Clinics, 25, 133-135. doi: 10.1016/j.det.2007.01.012
52. Wolf, S., Barton, D., Kottschade, L., Grothey, A., & Loprinzi, C. (2008). Chemotherapy-induced peripheral neuropathy: Prevention and treatment strategies. European Journal of Cancer, 44, 1507-1515. doi: 10.1016/j.ejca.2008.04.018